SHANGHÁI, HEIDELBERG (Alemania) y CAMBRIDGE (Massachusetts)–(BUSINESS WIRE)–Hengrui Pharma, una empresa farmacéutica internacional centrada en la innovación científica y tecnológica, y Novaliq GmbH («Novaliq»), una empresa biofarmacéutica especializa…
Category: Business
Riassunto: Heng Yi® di Hengrui è stata approvata in Cina come soluzione oftalmica innovativa di ciclosporina per il trattamento della malattia dell'occhio secco
SHANGHAI e HEIDELBERG, Germania e CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Hengrui Pharma, un’azienda farmaceutica globale che si concentra sull’innovazione scientifica e tecnologica, e Novaliq GmbH (“Novaliq”), un’azienda biofarmaceutica che si conc…
Le produit Heng Yi® de Hengrui obtient l’autorisation de mise sur le marché en Chine en tant que solution ophtalmique innovante à base de cyclosporine pour le traitement de la sécheresse oculaire
SHANGHAI et HEIDELBERG, Allemagne et CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Hengrui Pharma, une société pharmaceutique mondiale axée sur l’innovation scientifique et technologique, et Novaliq GmbH (« Novaliq »), une société biopharmaceutique spécia…
ZEISS Meditec Selects Atlas® System from Nirrin Technologies to Modernize Hyaluronic Acid Manufacturing Workflows
BILLERICA, Mass.–(BUSINESS WIRE)–Nirrin Technologies, a developer of analytical tools designed to transform bioprocess analytics, today announced that Hyaltech, a Carl ZEISS Meditec (CZM) company has purchased an Atlas® system to support hyaluronic a…
OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development
MIDDLETOWN, Pa.–(BUSINESS WIRE)– #DryAMD–OpZira™ appoints Scott Thielman, PhD, PE, as VP of Product Development to advance technologies for earlier detection and monitoring of ocular disease.
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics Lic…
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
SHANGHAI & HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)– #China–Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first…
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the …
Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced an oversubscribed $330 million Series B financing. The financing round was co…
Bayer Completes Acquisition of Perfuse Therapeutics
BERLIN–(BUSINESS WIRE)–Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously, Bayer now holds the full rights pertainin…
Vision Innovation Partners Appoints Dr. Brad Foster as Chief Medical and Strategy Officer
ANNAPOLIS, Md.–(BUSINESS WIRE)–Vision Innovation Partners (“VIP”), a leading Mid-Atlantic eye care platform with 69 locations, today announced that it has appointed Dr. Brad Foster as Chief Medical and Strategy Officer. The Chief Medical and Strategy…
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vi…
OpenEvidence and the American Academy of Ophthalmology Partner to Close the Gap Between Evidence and Eye Care
MIAMI & SAN FRANCISCO–(BUSINESS WIRE)– #ClinicalAI–The American Academy of Ophthalmology, the world’s largest association of eye physicians and surgeons, and OpenEvidence, the most widely used medical AI platform among U.S. physicians, today announc…
Mosaic Clinical Technologies™ Launches Mosaic Reporting™, an AI-Native Reporting Platform Built for Radiology Workflows
NASHVILLE, Tenn.–(BUSINESS WIRE)–Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, today announced the commercial launch of Mosaic Reporting™, a new class of AI-native radiology reporting solution available as part of Mo…
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in PCED
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé advances Phase 3 study of Cenegermin-bkbj (a rhNGF) for PCED, a rare condition with high unmet clinical need.
Eyebot and The Framery at 1-800 Contacts Announce Partnership in Greater Salt Lake City area, Delivering Doctor-Reviewed Glasses Prescriptions in Minutes
SALT LAKE CITY–(BUSINESS WIRE)–Eyebot and The Framery at 1-800 Contacts today announced a new partnership kicking off in The Framery’s hometown of Salt Lake City, Utah. Beginning June 3, Eyebot Kiosks will be open at Layton Hills Mall in Layton, Utah…
Phosio Raises $4 Million Seed Round to Bring Affordable AR/AI Glasses to Mass Market
CORVALLIS, Ore.–(BUSINESS WIRE)–Phosio raised $4M to advance lightweight AR glasses with integrated displays using its proprietary thin-film platform and advanced materials.
TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed
CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track…
Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at Clinical Trials at the Summit 2026
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinic…
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M…